Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Executive Summary
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.
You may also be interested in...
Drug Pricing: With "Value" Debate In Full Swing, ICER’s Influence Grows
The Institute for Clinical and Economic Review has invited feedback on its methodology for calculating a drug's recommended price range. Industry response has been critical, but pharma can no longer afford to merely oppose value frameworks. It needs to create strategies for a world in which such frameworks are a permanent and influential part of the pricing and reimbursement landscape.
Clinton Transition Co-Chair Tanden Offers Themes For A Drug Pricing Bill In 2017
FAIR Drug Pricing Act, CAP proposal and Collins bill include viable legislative movers for next administration. CMS Acting Administrator Slavitt signals that Part B demo will move forward based on CBO score.
The Clinton Drug Price Board, 23 Years Later
Hillary Clinton is reviving an idea she first endorsed in 1993: a drug price oversight board, but the focus has changed. While the pharma industry isn’t about to embrace any federal oversight board, the new Clinton plan is a lot less threatening than the old one.